GOSS News and Press, Gossamer Bio Inc. From 03/12/24

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced...

2024-03-05 07:38:38 ET More on Gossamer Bio Seeking Alpha’s Quant Rating on Gossamer Bio Historical earnings data for Gossamer Bio Financial information for Gossamer Bio Read the full article on Seeking Alpha For further details see: Gossam...

- First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA - - Cash, cash equivalents and marketable securities totaled $296 million at year-end 2023 - Gossamer Bio, Inc. (Nas...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and anal...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it has granted stock options to Bob Smith, Gossamer’s newly appoi...

- Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceut...

2023-11-15 12:52:53 ET Penny stocks are often priced under $5 per share. They attract traders seeking big gains. But, these stocks also carry significant risks. One smart strategy is to track insider trading via SEC filings. Insiders, like directors and officers, often access vital, non...

2023-11-15 11:28:35 ET Gossamer Bio ( NASDAQ: GOSS ) disclosed on Tuesday its COO/CFO Bryan Giraudo bought 200K common shares at $0.5644/share for ~$112.9K. Shares of GOSS rose 26.9% on Wednesday. SEC Filing For further details see: Gossamer Bio...

2023-11-09 07:51:10 ET More on Gossamer Bio Seeking Alpha’s Quant Rating on Gossamer Bio Historical earnings data for Gossamer Bio Financial information for Gossamer Bio For further details see: Gossamer Bio GAAP EPS of -$0.21 beats by $0.05

- Phase 3 PROSERA Site Activations Proceeding Ahead of Schedule; First Dosing Expected in 4Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 - - $329 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2023 - Gossa...